News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
254,065 Results
Type
Article (25061)
Company Profile (123)
Press Release (228881)
Section
Business (66588)
Career Advice (512)
Deals (11168)
Drug Delivery (35)
Drug Development (48787)
Employer Resources (40)
FDA (6328)
Job Trends (5638)
News (129722)
Policy (10499)
Tag
Academia (1522)
Africa (215)
Alliances (20114)
Alzheimer's disease (586)
Antibody-drug conjugate (ADC) (49)
Approvals (6297)
Artificial intelligence (40)
Asia (16892)
Australia (3277)
Bankruptcy (89)
Best Places to Work (4970)
Biotechnology (109)
Breast cancer (53)
C2C Services and Suppliers (16072)
California (999)
Canada (437)
Cancer (516)
Career advice (437)
CAR-T (56)
Cell therapy (163)
China (96)
Clinical research (36839)
Collaboration (113)
Colorado (36)
Connecticut (34)
COVID-19 (1300)
Cystic fibrosis (61)
Data (300)
Diabetes (36)
Diagnostics (2186)
Earnings (23782)
Employer resources (36)
Europe (37096)
Events (36931)
Executive appointments (71)
FDA (6485)
Florida (123)
Funding (83)
Gene editing (34)
Gene therapy (92)
GLP-1 (216)
Government (1443)
Healthcare (7149)
Hotbed/Location (166948)
Illinois (68)
Infectious disease (1317)
Inflammatory bowel disease (51)
Interviews (109)
IPO (5575)
Job creations (794)
Job search strategy (366)
Kansas (50)
Layoffs (146)
Legal (1343)
Liver cancer (47)
Lung cancer (129)
Maine (36)
Manufacturing (48)
Maryland (185)
Massachusetts (790)
Medical device (2828)
Medtech (2831)
Mergers & acquisitions (5605)
Metabolic disorders (95)
Michigan (52)
Minnesota (92)
Neuroscience (691)
New Jersey (360)
New York (343)
NextGen Class of 2024 (2250)
Non-profit (1209)
North Carolina (262)
Northern California (452)
Obesity (50)
Ohio (50)
Opinion (81)
Patents (40)
Pennsylvania (303)
People (17757)
Phase I (13438)
Phase II (16844)
Phase III (11029)
Pipeline (84)
Postmarket research (938)
Preclinical (6276)
Press Release (62)
Radiopharmaceuticals (110)
Rare diseases (121)
Real estate (1655)
Regulatory (8255)
Research institute (1443)
Resumes & cover letters (69)
South America (342)
Southern California (392)
Startups (1496)
Texas (121)
United States (4304)
Vaccines (241)
Washington State (220)
Weight loss (38)
Date
Today (66)
Last 7 days (306)
Last 30 days (1370)
Last 365 days (18656)
2024 (13624)
2023 (19871)
2022 (25025)
2021 (26136)
2020 (22721)
2019 (17089)
2018 (12985)
2017 (13399)
2016 (12188)
2015 (14506)
2014 (10000)
2013 (8314)
2012 (8430)
2011 (8399)
2010 (7210)
254,065 Results for "nature cell".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a scientific article in Nature Communications, unveiling a non-viral gene therapy approach for sickle cell disease.
June 12, 2024
·
5 min read
Biotech Bay
Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology
Kyverna Therapeutics, Inc. announced the publication in Nature Reviews Immunology of a manuscript co-authored with the National Institutes of Health titled “Chimeric antigen receptor T cell therapy for autoimmune disease”.
June 10, 2024
·
5 min read
Press Releases
Sana Biotechnology Highlights Publication in Nature Biotechnology of Novel In Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation
Sana Biotechnology, Inc. today highlighted that Nature Biotechnology has published a paper titled “Young glial progenitor cells competitively replace aged and diseased human glia in the adult chimeric mouse brain.”
May 21, 2024
·
6 min read
Policy
Replay and MD Anderson announce FDA clearance of IND application for first-in-class PRAME-targeted T-Cell Receptor Natural Killer (TCR-NK) cell therapy for hematological malignancies
Replay and The University of Texas MD Anderson Cancer Center, announced that the Food & Drug Administration has issued a ‘safe to proceed’ for the Investigational New Drug application for PRAME TCR/IL-15 NK, an engineered T-Cell Receptor Natural Killer cell therapy for relapsed/refractory myeloid malignancies.
April 30, 2024
·
5 min read
Press Releases
GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions
September 30, 2024
·
6 min read
Pharm Country
Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental CellsCompany Presenting at ASGCT Annual Meeting
Celularity Inc. (NASDAQ: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that it will present in vitro data from its investigational natural killer (NK) cell therapy programs at this year’s American Society of Gene and Cell Therapy (ASGCT) Annual Meeting.
April 8, 2024
·
5 min read
Drug Development
INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
INmune Bio, Inc. continues to advance its Natural Killer (NK) cell therapy, INKmune™, in a Phase I/II trial for men with metastatic castration-resistant prostate cancer (mCRPC).
April 29, 2024
·
6 min read
Therapeutic Solutions International Granted Patent on Commercially Available QuadraMune® Nutraceutical for Increasing Natural Killer Cell Immunity in COVID-19 Patients
Therapeutic Solutions International, Inc. announced today the granting of a patent covering the ability of QuadraMune® and similar compositions, to stimulate natural killer (NK) cell activity in patients with COVID-19.
March 4, 2024
·
2 min read
Drug Delivery
The Next Frontier: Industrializing Cell Therapy Manufacturing
Q&A: Development Scientist at AGC Biologics Sara Morlacchi analyzes the growth of the cell therapy industry and barriers for cost and accessibility.
April 29, 2024
·
7 min read
·
Sara Morlacchi, Cell Process Development Manager, AGC Biologics
Drug Development
N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study
ImmunityBio (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced data from a Phase 1 pilot study showed N-803 combined with natural killer cells could have the potential to reduce viral load in people living with HIV.
March 5, 2024
·
7 min read
1 of 25,407
Next